TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32823413
Drug: Anti-VEGF treatment
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF treatment (Group B)
Study: 32823413
Drug: No anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No anti-VEGF treatment (Group A)
Study: 36031115
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) stimulation
Study: 32776244
Drug: tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.4 mg once daily for 6 months
Study: 32776244
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no α-blockers)
Study: 35073298
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy to hands and feet during chemotherapy
Study: 35073298
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (no cold therapy)
Study: 32329198
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied with GaAlAs laser (808 nm, avg. power density: 50 mW, 66 J total dose)
Study: 35993547
Drug: Concurrent or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent or pooled controls
Study: 32789901
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) book study
Study: 32789901
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) training without SP/SR
Study: 35341432
Drug: Controller medications
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controller medications adherence
Study: 35341432
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid bursts
Study: 35291405
Drug: Ropivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (5 cc of 0.25% solution)
Study: 35291405
Drug: Ropivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (5 cc of 0.25% solution) plus dexmedetomidine (0.5 µg/kg)
Study: 36163982
Drug: Add-on parsaclisib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on parsaclisib 10 or 20 mg QD for 8 weeks then same dose QW
Study: 36163982
Drug: Add-on parsaclisib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on parsaclisib 5 or 20 mg QD for 8 weeks then 5 mg QD
Study: 35512402
Drug: Pertuzumab added
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab added to adjuvant chemotherapy plus trastuzumab
Study: 35512402
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (adjuvant chemotherapy plus trastuzumab without pertuzumab)
Study: 35837711
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg every 2 weeks for 2 to 6 weeks before PCI
Study: 35226723
Drug: Canakinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (300 mg subcutaneous, 6 monthly treatments)
Study: 33792896
Drug: 1% glycopyrronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% glycopyrronium bromide cream applied for 4 weeks
Study: 33792896
Drug: 0.5%, 1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5%, 1%, and 2% glycopyrronium bromide cream applied topically for 2 weeks
Study: 34097448
Drug: Therapeutics targeting
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutics targeting HDL metabolism
Study: 32094219
Drug: Basic cost
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic cost group (GP stated the weekly monetary cost)
Study: 32094219
Drug: Cost comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost comparison group (GP compared weekly cost to an everyday discretionary item)
Study: 32068354
Drug: BMS-986184 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986184 (150 mg subcutaneously every other week)
Study: 37661535
Drug: Havisure™ vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havisure™ vaccine
Study: 32639235
Drug: RHB-102 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: RHB-102 (12 mg daily)
Study: 34625591
Drug: Experimental implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental implant design
Study: 34625591
Drug: Control implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implant design
Study: 34843069
Drug: Umbilical cord-derived
Normalized name: Allogenic umbilical cord-derived mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment, administered as three infusions at 4-week intervals plus conventional treatment.
Study: 34843069
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving conventional treatment only.
Study: 34843069
Drug: UC-MSC treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC treatment.
Study: 32618578
Drug: Delay group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay group (DG) received a monthly electronic newsletter in weeks 1 to 12 and started the same intervention in week 14.
Study: 35811347
Drug: Atomoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine plus fesoterodine (80-4 mg)
Study: 34127041
Drug: Educational pre-visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational pre-visit preparation (PVP) + usual care
Study: 36034207
Drug: Entresto 50
Normalized name: Entresto
DrugBank: Sacubitril (DB09292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Entresto 50 mg + basic treatment
Study: 34164855
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of crocin
Study: 32820431
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges administered twice daily for 5 days (subgroup AI)
Study: 32820431
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges administered twice daily for 5 days (subgroup BI)
Study: 33501741
Drug: Doxycycline treatment
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline treatment (antibiotic group)
Study: 33501741
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (non-antibiotic group)
Study: 32982191
Drug: Monthly professional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly professional cleaning and individual oral hygiene instructions by registered dental hygienists (RDHs)
Study: 32982191
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral care as usual (self‐performed or nursing staff‐assisted)
Study: 33486762
Drug: Classical Hodgkin
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical Hodgkin lymphoma (cHL) treatment
Study: 35436970
Drug: Inverse-probability-of-treatment weighting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inverse-probability-of-treatment weighting (IPTW)
Study: 33909857
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) following their own daily activities
Study: 33280968
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education and decision aid tool about prescription pain relievers (N = 65)
Study: 33620550
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (200 mg/day)
Study: 36085061
Drug: OAD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAD with antihypertensive drugs (test group)
Study: 34606574
Drug: Topical racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical racemic epinephrine pellets
Study: 32022954
Drug: Clinical investigations
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical investigations and surgical treatments
Study: 34547486
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (0.25 mL rabies vaccine at day 0, 7 with IIV4)
Study: 34547486
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (0.25 mL rabies vaccine at day 0, 28 with IIV4)
Study: 34547486
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (0.25 mL rabies vaccine at day 0, 7)
Study: 32858111
Drug: Insulin Use
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Use
Study: 32858111
Drug: CA19-9 ≥90
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA19-9 ≥90 U/mL
Study: 37700241
Drug: Dose-response relationship
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response relationship
Study: 34661774
Drug: Graftless sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graftless sinus augmentation
Study: 34661774
Drug: Conventional sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sinus augmentation (autografts and xenografts)
Study: 32846768
Drug: Baduanjin exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baduanjin exercise combined with standardized drug therapy
Study: 32846768
Drug: Routine exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine exercise combined with standardized drug therapy
Study: 35641218
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice (IC) of chemotherapy (n = 26)
Study: 34537494
Drug: SPECT/CT aided
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECT/CT aided botulinum toxin injection
Study: 35259978
Drug: Topiramate monotherapy
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate monotherapy 100 mg/day (group A)
Study: 35259978
Drug: Topiramate plus
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate plus greater occipital nerve block with 40 mg lidocaine (2%) and 80mg (2 ml) methylprednisolone (group B)
Study: 35259978
Drug: Topiramate plus
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate plus greater occipital nerve block with 40 mg lidocaine (2%) injections monthly for 3 months (group C)
Study: 32413595
Drug: Antidepressant medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medications (MEDs)
Study: 34378245
Drug: Fuzuloparib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzuloparib 50 mg (test preparation)
Study: 34378245
Drug: Reference preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparations (10 mg, 40 mg, 100 mg)
Study: 32111264
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules once daily for 6 months
Study: 32552153
Drug: Empagliflozin/linagliptin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin/linagliptin combination
Study: 32410463
Drug: Empagliflozin monotherapy
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin monotherapy
Study: 33112433
Drug: 50mg daily
Normalized name: PIQRAY 250mg Daily Dose Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg daily oral avanafil
Study: 34479835
Drug: N-acetylcysteine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (400 mg/d)
Study: 34479835
Drug: Clonazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5 mg/d)
Study: 33919779
Drug: Carbohydrate-rich meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich meal (CARB; 1 g/kg CHO)
Study: 33919779
Drug: Protein-rich meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich meal (PROTEIN; 0.45 g/kg protein + 0.24 g/kg fat)
Study: 33754864
Drug: Conidial suspensions
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conidial suspensions of L. biglobosa 'brassicae' and 'canadensis' (10 μL, 1 × 10^7 conidia mL‐1) inoculated on needle‐wounded cotyledons of B. napus cultivar Zhongshuang No. 9.
Study: 36123113
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) medication (Epidiolex)
Study: 33905350
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy as usual (FTAU)
Study: 33120482
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal expansion suppository (150 mg) daily at night for 7 days
Study: 33120482
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal tablet (500 mg) single dose
Study: 32339648
Drug: Avelumab plus
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab plus axitinib (10 mg/kg intravenously every 2 weeks plus 5 mg orally twice daily)
Study: 32339648
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg orally once daily for 4 weeks)
Study: 34033212
Drug: Ipragliflozin 50
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 50 mg once daily
Study: 36053447
Drug: Conventional Fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Fluid Therapy (Control)
Study: 36217159
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate (RAS)
Study: 36217159
Drug: Post-referral parenteral
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-referral parenteral antimalarials plus oral artemisinin-based combination therapy (ACT)
Study: 32278779
Drug: Inhaled regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled regimens aligning with GOLD recommendations
Study: 33994285
Drug: Gel support
Normalized name: CAMPHOR (SYNTHETIC) 2.8 g in 100 g / MENTHOL, UNSPECIFIED FORM 2.25 g in 100 g TOPICAL GEL [Sno Swedish Arctic Gel Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel support surface
Study: 33530854
Drug: Chia seeds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chia seeds (40 g/day for 12 weeks)
Study: 34851445
Drug: Oral triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triiodothyronine (T3, Tetronine®) 1 μg/kg-body weight/dose every 6 hours for 60 hours
Study: 34851445
Drug: Oral triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triiodothyronine (T3) in low-risk patients (Aristotle score < 10.0)
Study: 34851445
Drug: Oral triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triiodothyronine (T3) in low-risk patients
Study: 32878448
Drug: FV-only weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FV-only weekly vouchers
Study: 32147519
Drug: Postmastectomy hypofractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmastectomy hypofractionated radiation therapy (HFRT; 43.5 Gy in 15 fractions over 3 weeks)
Study: 34068083
Drug: 12-weekly BTA
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-weekly BTA dosing
Study: 34068083
Drug: 4-weekly BTA
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4-weekly BTA dosing
Study: 34068083
Drug: De-escalation from
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation from 4-weekly to 12-weekly BTA
Study: 32628583
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab
Study: 36177501
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tadalafil daily
Study: 36177501
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tadalafil 2 hours before sexual relations twice a week
Study: 36177501
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tadalafil daily + 15 mg tadalafil 2 hours before sexual relations twice a week
Study: 32007823
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system inhibitor beyond 1 year
Study: 32725573
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate associated with paracetamol
Study: 32755802
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) targeting the ventral anterior limb of the internal capsule
Study: 35690690
Drug: GHD before
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHD before treatment
Study: 35100279
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (No pretreatment)
Study: 33032883
Drug: Steroid-free arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free arm (Basiliximab + Tacrolimus + Azathioprine)
Study: 33032883
Drug: Steroid arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid arm (Steroid + Tacrolimus + Azathioprine)
Study: 34275239
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang (JHWK) (14 days of quadruple therapy + 30 days of JHWK)
Study: 34275239
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (14 days)
Study: 34275239
Drug: All enrolled
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled patients post-treatment
Study: 34275239
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group post-treatment
Study: 34275239
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group post-treatment
Study: 32517785
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure self-management (daily home blood pressure monitoring and automated medication reduction via telemonitoring)
Study: 34116351
Drug: LPS challenge
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS challenge (0.4 mg/kg)
Study: 34116351
Drug: LPS challenge
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS challenge (0.1, 0.2, and 0.8 mg/kg)
Study: 34409620
Drug: Nasal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal treatment using pure oxybuprocaine gel with adequate lubrication (group G)
Study: 34409620
Drug: 1% ephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ephedrine in addition to oxybuprocaine gel with adequate lubrication (group EG)
Study: 35766039
Drug: Continuous care
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous care combined with optimized insulin injection techniques
Study: 34130395
Drug: Robenacoxib 2
Normalized name: robenacoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robenacoxib 2 mg/kg IM
Study: 35283454
Drug: Quadruple low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple low calcineurin inhibitor (CNI) regimen
Study: 33878772
Drug: Caffeine treatment
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine treatment in the first 24 hours (group 1)
Study: 33878772
Drug: Caffeine treatment
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine treatment at the 72nd hour (group 2)
Study: 34992346
Drug: AD-206 (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD-206 (esomeprazole 20 mg or 40 mg + calcium carbonate 600 mg)
Study: 35797000
Drug: Underwater walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Underwater walking therapy
Study: 35654466
Drug: Standard (reactive)
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard (reactive) induction therapy with ixazomib, lenalidomide, and dexamethasone (IRD)
Study: 35654466
Drug: Frailty-adjusted (adaptive)
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frailty-adjusted (adaptive) induction therapy with ixazomib, lenalidomide, and dexamethasone (IRD)
Study: 35654466
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with lenalidomide+ixazomib
Study: 35654466
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with lenalidomide+placebo
Study: 32597373
Drug: Challenge condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Challenge condition (n=40) received daily emails for 24 days highlighting a particular strength, its value, implementation strategies, and a motto.
Study: 32597373
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (n=35) received daily emails containing only the motto for each strength for 24 days.
Study: 33607813
Drug: Ketorolac plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac plus Lidocaine (30 mg Ketorolac and 2% Lidocaine - adrenaline)
Study: 33090904
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to biological dust